The pathogenesis and treatment of nonalcoholic fatty liver diseases - From fatty liver to cirrhosis;Pathogenese und Therapie der nichtalkoholischen Fettlebererkrankungen - Von der Fettleber zur Zirrhose

Deutsches Arzteblatt

Volumn 103, Issue 19, 2006, Pages

  Dancygier, Henryk ^a  

^a Klinikum Offenbach   (Germany)

Author keywords

Insulin resistance; Liver disease; Metabolic syndrome; NAFLD; Steatohepatitis

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLCYSTEINE; ALPHA TOCOPHEROL; AMINOTRANSFERASE; AMIODARONE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIRETROVIRUS AGENT; BETAINE; CHLOROQUINE; COTRIMOXAZOLE; ESTROGEN DERIVATIVE; GLUCOCORTICOID; METFORMIN; NIFEDIPINE; PENTOXIFYLLINE; PIOGLITAZONE; ROSIGLITAZONE; TROGLITAZONE; URSODEOXYCHOLIC ACID;

AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CLINICAL TRIAL; DIABETES MELLITUS; DISEASE ASSOCIATION; HUMAN; INDUSTRIALIZATION; INSULIN RESISTANCE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DYSFUNCTION; LIVER FIBROSIS; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; OBESITY; PATHOGENESIS; PATIENT CARE; STEATOSIS; VISCERA; WEIGHT REDUCTION;

EID: 33646720295     PISSN: 00121207     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Neuschwander-Tetri BA, Caldwell SH: Nonalcoholic steatohepatitis: summary of an AASLD single topic conference. Hepatology 2003; 37: 1202-19.
2. Dancygier H: "Alkoholische" Leberschäden bei Nichtalkoholikern. Nichtalkoholische Steatohepatitis. Dtsch Med Wochenschr 1997; 122: 1183-8.
3. Bellentani S, Bedogni G, Miglioli L, Tiribelli C: The epidemiology of fatty liver. Eur J Gastroenterol Hepatol 2004; 16: 1087-93.
4. Bacon BR, Farahvash MJ, Janney CG, Neuschwander-Tetri BA: Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 1994; 107: 1103-09.
5. Rashid M, Roberts E: Nonalcoholic steatohepatitis in children. J Pediatr Gastroenterol Nutr 2000; 30: 48-53.
6. Marchesini G, Bugianesi E, Forlani G et al.: Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003; 37: 917-23.
7. Day CP, James OF: Steatohepatitis: a tale of two "hits"? Gastroenterology 1998; 114: 842-5.
8. Chitturi S, Abeygunasekera S, Farrell GC et al.: NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002; 35: 373-9.
9. Pagano G, Pacini G, Musso G et al.: Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. Hepatology 2002; 35: 367-72.
10. Sanyal AJ, Campbell-Sargent C, Mirshahi F et al.: Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001; 120: 1183-92.
11. Horton JD, Goldstein JL, Brown MS: SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 2002; 109: 1125-31.
12. Charlton M, Sreekumar R, Rasmussen D, Lindor K, Nair KS: Apolipoprotein synthesis in nonalcoholic steatohepatitis. Hepatology 2002; 35: 898-904.
13. Feldstein AE, Canbay A, Angulo P et al.: Hepatocyte apoptosis and Fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 2003; 125: 437-43.
14. Pessayre D, Fromenty B, Mansouri A: Mitochondrial injury in steatohepatitis. Eur J Gastroenterol Hepatol 2004; 16: 1095-105.
15. Perez-Carreras M, Del Hoyo P, Martin MA et al.: Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis. Hepatology 2003; 38: 999-1007.
16. Weltman MD, Farrell GC, Hall P, Ingelman-Sundberg M, Liddle C: Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis. Hepatology 1998; 27: 128-33.
17. Ceddia RB, Koistinen HA, Zierath JR, Sweeney G: Analysis of paradoxical observations on the association between leptin and insulin resistance. FASEB J 2002; 16: 1163-76.
18. Chalasani N, Crabb DW, Cummings OW et al.: Does leptin play a role in the pathogenesis of human nonalcoholic steatohepatitis? Am J Gastroenterol 2003; 98: 2771-6.
19. Kaser S, Moschen A, Cayon A et al: Adiponectin and its receptors in non-alcoholic steatohepatitis. Gut 2005; 54: 117-21.
20. Teli MR, James OFW, Burt AD, Bennett MK, Day CP: The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology 1995; 22: 1714-9.
21. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ: Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413-9.
22. Harrison SA, Torgerson S, Hayashi PH: The natural history of nonalcoholic fatty liver disease: a clinical histopathological study. Am J Gastroenterol 2003; 98: 2042-7.
23. Powell EE, Cooksley WG, Hanson R, Searle J, Halliday JW, Powell LW: The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 1990; 11: 74-80.
24. Davila JA, Morgan RO, Shaib Y, McGlynn KA, ElSerag HB: Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut 2005; 54: 533-9.
25. Lindor KD, Kowdley KV, Heathcote EJ et al.: Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology 2004; 39: 770-8.